Venaxis files for FDA authorization of appendicitis test

Venaxis (APPY +1.6%) has filed for FDA 510(k) approval of its APPY1 Test for identifying patients who are at low risk of appendicitis.

The submission comes after APPY1 performed well in a pivotal trial, with sensitivity and negative predictive value results surpassing those in a pilot study. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs